Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 18/2014

01-12-2014 | Adis Drug Evaluation

Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus

Author: Lesley J. Scott

Published in: Drugs | Issue 18/2014

Login to get access

Abstract

Subcutaneous liraglutide (Victoza®), a glucagon-like peptide 1 receptor agonist, is approved for the treatment of adult patients with type 2 diabetes mellitus. Once-daily liraglutide, as monotherapy or add-on therapy to other antidiabetic agents (including basal insulin), was an effective and generally well tolerated treatment in adult patients with type 2 diabetes in several well-designed phase III trials and in the real world clinical practice setting. In addition to improving glycaemic control, liraglutide had beneficial effects on bodyweight, systolic blood pressure and surrogate measures of β-cell function in clinical trials, with these benefits maintained during long-term treatment (≤2 years). Liraglutide has a convenient once-daily administration regimen, a low potential for drug–drug interactions and low propensity to cause hypoglycaemia. Thus, liraglutide continues to be a useful option for the management of type 2 diabetes. This article reviews the therapeutic use of liraglutide in adult patients with type 2 diabetes and summarizes its pharmacological properties.
Literature
1.
American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014;37(Suppl 1):S14–80.CrossRef
2.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.PubMedCentralPubMedCrossRef
3.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm. Endocr Pract. 2013;19(2):327–36.PubMedCentralPubMed
4.
5.
6.
7.
8.
Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab. 2012;14(4):304–14.PubMedCentralPubMedCrossRef
9.
Nauck M. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med. 2011;124(Suppl):S3–18.PubMedCrossRef
10.
Perry CM. Liraglutide: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2011;71(17):2347–73.PubMedCrossRef
11.
Croom KF, McCormack PL. Liraglutide: a review of its use in type 2 diabetes mellitus. Drugs. 2009;69(14):1985–2004.PubMedCrossRef
12.
13.
14.
Flint A, Kapitza C, Zdravkovic M. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment. Diabetes Obes Metab. 2013;15(10):958–62.PubMedCrossRef
15.
Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(2):258–66.PubMedCrossRef
16.
Hermansen K, Baekdal TA, During M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15(11):1040–8.PubMedCrossRef
17.
Buse JB, Garber A, Rosenstock J, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96(6):1695–702.PubMedCrossRef
18.
Chatterjee DJ, Khutooryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol. 2009;49(11):1353–62.PubMedCrossRef
19.
Klein DJ, Battelino T, Chatterjee DJ, et al. Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Technol Ther. 2014;16(10):1–9.CrossRef
20.
Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–81.PubMedCrossRef
21.
Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.PubMedCentralPubMedCrossRef
22.
Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–78.PubMedCentralPubMedCrossRef
23.
Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32(7):1224–30.PubMedCentralPubMedCrossRef
24.
Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–56.PubMedCrossRef
25.
Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab. 2011;13(1):81–8.PubMedCrossRef
26.
Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(4):341–7.PubMedCrossRef
27.
Seino S, Rasmussen MF, Nishida T, et al. Efficacy and safety of once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010;26(5):1013–22.PubMedCrossRef
28.
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.PubMedCrossRef
29.
Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014;16(7):636–44.PubMedCrossRef
30.
DeVries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care. 2012;35:1446–54.PubMedCentralPubMedCrossRef
31.
Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–55.PubMedCentralPubMedCrossRef
32.
Aroda VR, Bailey T, Cariou B, et al. The effect of insulin degludec in combination with liraglutide and metformin in patients with type 2 diabetes requiring treatment intensification [abstract no. 145]. Diabetologia. 2014;57(Suppl 1):S68.
33.
Lahtela J, Ahmann A, Rodbard H, et al. Efficacy and safety of liraglutide vs. placebo when added to basal insulin analgoues in subjects with type 2 diabetes [abstract no. 37]. Diabetologia. 2014;57(Suppl 1):S21–2.
34.
Umpierrez G, Atkin S, Bain S, et al. Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomised trial [abstract no. 182]. Diabetologia. 2014;57(Suppl 1):S84.
35.
Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):348–56.PubMedCentralPubMedCrossRef
36.
Kaku K, Rasmussen MF, Nishida T, et al. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. J Diabetes Invest. 2011;2(6):441–7.CrossRef
37.
Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013;15(3):204–12.PubMedCrossRef
38.
Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65(4):397–407.PubMedCentralPubMedCrossRef
39.
Ross SA, Ballantine J. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes. Curr Med Res Opin. 2013;29(12):1617–26.PubMedCrossRef
40.
Seino S, Rasmussen MF, Nishida T, et al. Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: results of a 52-week, randomized controlled trial. J Diabetes Invest. 2011;2(4):280–6.CrossRef
41.
Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6):1300–3.PubMedCentralPubMedCrossRef
42.
Rosenstock J, Rodbard HW, Bain SC, et al. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complicat. 2013;27(5):492–500.PubMedCrossRef
43.
Nyeland ME, Ploug UJ, Skovgaard R, et al. Comparative effectiveness of liraglutide versus sitagliptin in type 2 diabetes in the United Kingdom: a retrospective study in primary care [abstract no. PDB3]. Value Health. 2013;16(7):A431.CrossRef
44.
DiGenio A, Ling Z, Davis KL, et al. Real-world characteristics of patients with type 2 diabetes initiating insulin glargine plus exenatide or insulin glargine plus liraglutide [abstract no. 797]. Diabetologia. 2012;55(Suppl 1):S328.
45.
Gupta PS, Thong KY, Armstrong M, et al. Does liraglutide therapy affect the metabolic response in patients with elevated alanine aminotransferase and type 2 diabetes mellitus? The ABCD nationwide liraglutide audit [abstract no. 1037-P]. Diabetes. 2013;62(Suppl):A267.
46.
47.
Lee WC, Dekoven M, Bouchard J, et al. Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. Diabetes Obes Metab. 2014;16(9):819–26.PubMedCrossRef
48.
Saunders W, Hiep Nguyen H, Kalsekar I. Real-world comparative effectiveness of exenatide once-weekly and liraglutide in patients with type 2 diabetes mellitus [abstract no. 828]. Diabetologia. 2014;57(Suppl 1):S335–6.
49.
Wangnoo SK, Mithal A, Kumar S, et al. Safety and efficacy of liraglutide in type 2 diabetes: post marketing surveillance data from India [abstract no. 732]. Diabetologia. 2012;55(Suppl 1):S299.
50.
Levin PA, Buysman E, Thayer S, et al. The INITIATOR study: real-world treatment patterns and outcomes in patients with type 2 diabetes initiating insulin glargine or liraglutide [abstract no. 111]. Diabetologia. 2014;57(Suppl 1):S53–4.
51.
Madani S, Charpentier G, Martinez L, et al. Effectiveness of switching from a DPP-4 inhibitor to the human GLP-1 analogue liraglutide in patients with type 2 diabetes: data from the EVIDENCE study [abstract no. 832]. Diabetologia. 2014;57(Suppl 1):S337.
52.
Gourdy P, Penfornis A, Charpentier G, et al. EVIDENCE 1 [abstract no. 840]. Diabetologia. 2014;57(Suppl 1):S341.
53.
Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2012;7(8):e42551.PubMedCentralPubMedCrossRef
54.
Stolar M. Glycemic control and complications in type 2 diabetes mellitus. Am J Med. 2010;123:S3–11.PubMedCrossRef
55.
Stolar M. Addressing cardiovascular risk in patients with type 2 diabetes: focus on primary care. Am J Med Sci. 2011;341(2):132–40.PubMedCrossRef
56.
57.
Marso SP, Poulter NR, Nissen SE, et al. Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome and results (LEADER) trial design and methods [abstract no. 74]. Diabetologia. 2013;56(Suppl 1):S37.
58.
Giorda CB, Sacerdote C, Nada E, et al. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2014. doi:10.​1007/​s12020-014-0386-8.
59.
Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62(7):2595–604.PubMedCentralPubMedCrossRef
60.
Yang L, He Z, Tang X, et al. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25(2):225–31.PubMedCrossRef
61.
Singh S, Chang H-Y, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534–9.PubMedCrossRef
62.
Nauck M. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013;36(7):2126–32.PubMedCentralPubMedCrossRef
63.
Nauck M, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care. 2013;36(Suppl 2):S245–S52.
64.
Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012;14(12):1123–8.PubMed
65.
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370(9):794–7.PubMedCrossRef
66.
Metadata
Title
Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus
Author
Lesley J. Scott
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 18/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-014-0321-6

Other articles of this Issue 18/2014

Drugs 18/2014 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees

Adis Drug Evaluation

Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes

Adis Drug Evaluation

Rifaximin: A Review of Its Use in Reducing Recurrence of Overt Hepatic Encephalopathy Episodes

Therapy in Practice

Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations

Adis Drug Evaluation

Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease

Leading Article

The Biology and Clinical Development of MEK Inhibitors for Cancer